Recent Progress on NIR-II Photothermal Therapy

Zhang, Yunguang; Zhang, Siyu; Zhang, Zihan; Ji, Lü; Zhang, Jiamei; Wang, Qihao; Guo, T.F.; Ni, Simin; Cai, Ru; Mu, Xiaoyu; Long, Wei; Wang, Hao

doi:10.3389/fchem.2021.728066

Cited by 78 publications

(70 citation statements)

References 134 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among them, PTT has been widely demonstrated as a prospective non-invasive therapeutic regimen for cancer. PTT delivers photosensitiser to tumor tissues with high light-to-heat conversion performance and uses near-infrared (NIR) light radiation to generate heat to kill cancer cells and suppress tumor growth [ 32 , 33 ].…”

Section: Introductionmentioning

confidence: 99%

Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer

et al. 2022

View full text Add to dashboard Cite

Background Triple-negative breast cancer (TNBC) is more prone to distant metastasis and visceral recurrence in comparison to other breast cancer subtypes, and is related to dismal prognosis. Nevertheless, TNBC has an undesirable response to targeted therapies. Therefore, to tackle the huge challenges in the diagnosis and treatment of TNBC, Nectin-4 was selected as a theranostic target because it was recently found to be highly expressed in TNBC. We developed anti-Nectin-4 monoclonal antibody (mAbNectin-4)-based theranostic pair, 99mTc-HYNIC-mAbNectin-4 and mAbNectin-4-ICG. 99mTc-HYNIC-mAbNectin-4 was applied to conduct immuno-single photon emission computed tomography (SPECT) for TNBC diagnosis and classification, and mAbNectin-4-ICG to mediate photothermal therapy (PTT) for relieving TNBC tumor growth. Methods Nectin-4 expression levels of breast cancer cells (MDA-MB-468: TNBC cells; and MCF-7, non-TNBC cells) were proved by western blot, flow cytometry, and immunofluorescence imagning. Cell uptake assays, SPECT imaging, and biodistribution were performed to evaluate Nectin-4 targeting of 99mTc-HYNIC-mAbNectin-4. A photothermal agent (PTA) mAbNectin-4-ICG was generated and characterized. In vitro photothermal therapy (PTT) mediated by mAbNectin-4-ICG was conducted under an 808 nm laser. Fluorescence (FL) imaging was performed for mAbNectin-4-ICG mapping in vivo. In vivo PTT treatment effects on TNBC tumors and corresponding systematic toxicity were evaluated. Results Nectin-4 is overexpressed in MDA-MB-468 TNBC cells, which could specifically uptake 99mTc-HYNIC-mAbNectin-4 with high targeting in vitro. The corresponding immunoSPECT imaging demonstrated exceptional performance in TNBC diagnosis and molecular classification. mAbNectin-4-ICG exhibited favourable biocompatibility, photothermal effects, and Nectin-4 targeting. FL imaging mapped biodistribution of mAbNectin-4-ICG with excellent tumor-targeting and retention in vivo. Moreover, mAbNectin-4-ICG-mediated PTT provided advanced TNBC tumor destruction efficiency with low systematic toxicity. Conclusion mAbNectin-4-based radioimmunoimaging provides visualization tools for the stratification and diagnosis for TNBC, and the corresponding mAbNectin-4-mediated PTT shows a powerful anti-tumor effect. Our findings demonstrate that this Nectin-4 targeting strategy offers a simple theranostic platform for TNBC.

show abstract

Section: Introductionmentioning

confidence: 99%

Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer

et al. 2022

View full text Add to dashboard Cite

show abstract

“…The PTFHD nanoplatforms lead to the local high temperature of mitochondria site under the irradiation of near-infrared laser (808 nm), which greatly promoted the rate of the Fenton reaction and damages the mitochondria. The second near-infrared (1,000–1,350 nm, NIR-II) has deeper tissue penetration and higher maximum allowable exposure than the first near-infrared (750–1,000 nm, NIR-I) light ( Wang et al, 2021e ; Liu et al, 2021 ; Zhang et al, 2021 ). Very recently, Li et al (2021c) developed mitochondria-targeted MoS 2 @PDA-Fe@PEG/TPP nanosheets (MPFPT NSs) for the combination therapy of NIR-II-activated PTT and CDT.…”

Section: Ht Enhanced M-cdt Nanodrugsmentioning

confidence: 99%

Mitochondria-Targeting Chemodynamic Therapy Nanodrugs for Cancer Treatment

Chen

Wang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Mitochondria, as one of the most critical subcellular organelles of cancer cells, are very vulnerable and often on the verge of oxidative stress. The classic chemodynamic therapy (CDT) directly employs endogenous chemical energy to trigger reactive oxygen species (ROS) burst and destroy tumor cells. However, the effectiveness of CDT is restricted by the limited diffusion distance and short half-life of ROS. From this perspective, the treatment method (mitochondria-targeting chemodynamic therapy nanodrugs, M-CDT nanodrugs) that can generate high levels of ROS at the mitochondrial site is extremely efficient and promising for cancer treatment. Currently, many emerging M-CDT nanodrugs have been demonstrated excellent spatial specificity and anti-cancer efficacy. In this minireview, we review various proof-of-concept researches based on different M-CDT nanodrugs designs to overcome the limits of the efficacy of CDT, mainly divided into four strategies: supplying H2O2, non-H2O2 dependent CDT, eliminating GSH and enhancing by hyperthermia therapy (HT). These well-designed M-CDT nanodrugs greatly increase the efficacy of CDT. Finally, the progress and potential of M-CDT nanodrugs are discussed, as well as their limitations and opportunities.

show abstract

“…The properties in these three pathways are competitive in the nanomaterials. According to the applications, near-infrared photosensitizers are classified into inorganic (gold nanomaterials, two-dimensional materials, metal oxide materials, and quantum dots) and organic (polymers) types [86].…”

Section: Phototherapy and Other Therapiesmentioning

confidence: 99%

Progress and Viewpoints of Multifunctional Composite Nanomaterials for Glioblastoma Theranostics

et al. 2022

View full text Add to dashboard Cite

The most common malignant tumor of the brain is glioblastoma multiforme (GBM) in adults. Many patients die shortly after diagnosis, and only 6% of patients survive more than 5 years. Moreover, the current average survival of malignant brain tumors is only about 15 months, and the recurrence rate within 2 years is almost 100%. Brain diseases are complicated to treat. The reason for this is that drugs are challenging to deliver to the brain because there is a blood–brain barrier (BBB) protection mechanism in the brain, which only allows water, oxygen, and blood sugar to enter the brain through blood vessels. Other chemicals cannot enter the brain due to their large size or are considered harmful substances. As a result, the efficacy of drugs for treating brain diseases is only about 30%, which cannot satisfy treatment expectations. Therefore, researchers have designed many types of nanoparticles and nanocomposites to fight against the most common malignant tumors in the brain, and they have been successful in animal experiments. This review will discuss the application of various nanocomposites in diagnosing and treating GBM. The topics include (1) the efficient and long-term tracking of brain images (magnetic resonance imaging, MRI, and near-infrared light (NIR)); (2) breaking through BBB for drug delivery; and (3) natural and chemical drugs equipped with nanomaterials. These multifunctional nanoparticles can overcome current difficulties and achieve progressive GBM treatment and diagnosis results.

show abstract

Recent Progress on NIR-II Photothermal Therapy

Cited by 78 publications

References 134 publications

Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer

Nectin-4-targeted immunoSPECT/CT imaging and photothermal therapy of triple-negative breast cancer

Mitochondria-Targeting Chemodynamic Therapy Nanodrugs for Cancer Treatment

Progress and Viewpoints of Multifunctional Composite Nanomaterials for Glioblastoma Theranostics

Contact Info

Product

Resources

About